TRAIL receptor signalling and modulation: Are we on the right TRAIL?
about
Onto better TRAILs for cancer treatmentMesenchymal stem cells as vectors for lung cancer therapyThe Janus Face of Death Receptor Signaling during Tumor ImmunoeditingApoptosis-Related Gene Expression in an Adult Cohort with Crimean-Congo Hemorrhagic Fever.CHM-1, a new vascular targeting agent, induces apoptosis of human umbilical vein endothelial cells via p53-mediated death receptor 5 up-regulation.PPARγ activation by troglitazone enhances human lung cancer cells to TRAIL-induced apoptosis via autophagy fluxEarly growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells.Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors.HIV infection enhances TRAIL-induced cell death in macrophage by down-regulating decoy receptor expression and generation of reactive oxygen species.miR-942 decreases TRAIL-induced apoptosis through ISG12a downregulation and is regulated by AKT.Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression.Caspases: a molecular switch node in the crosstalk between autophagy and apoptosisTRAIL treatment provokes mutations in surviving cells.TL1-A can engage death receptor-3 and activate NF-kappa B in endothelial cells.Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants.Clerodane diterpenes from Casearia arguta that act as synergistic TRAIL sensitizersBisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulationSynergistic Effect of Subtoxic-dose Cisplatin and TRAIL to Mediate Apoptosis by Down-regulating Decoy Receptor 2 and Up-regulating Caspase-8, Caspase-9 and Bax Expression on NCI-H460 and A549 Cells.Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis.Amyloid-β precursor protein promotes cell proliferation and motility of advanced breast cancer.Apoptotic cell signaling in cancer progression and therapyChestnut extract induces apoptosis in AGS human gastric cancer cells.Co-acting gene networks predict TRAIL responsiveness of tumour cells with high accuracy.Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4.Controlled delivery of BID protein fused with TAT peptide sensitizes cancer cells to apoptosis.TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill.Synergistic TRAIL sensitizers from Barleria alluaudii and Diospyros maritima.Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL.An added dimension to tumour TRAIL sensitivity.Ultrasound-stimulated microbubble enhancement of radiation treatments: endothelial cell function and mechanism.Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.The oncogene metadherin modulates the apoptotic pathway based on the tumor necrosis factor superfamily member TRAIL (Tumor Necrosis Factor-related Apoptosis-inducing Ligand) in breast cancer.Inositol pyrophosphates as mammalian cell signalsThe pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells.Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways.Altered expression of mir-222 and mir-25 influences diverse gene expression changes in transformed normal and anaplastic thyroid cells, and impacts on MEK and TRAIL protein expression.Trail overexpression inversely correlates with histological differentiation in intestinal-type sinonasal adenocarcinoma.Guiding TRAIL to cancer cells through Kv10.1 potassium channel overcomes resistance to doxorubicin.Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane
P2860
Q26768160-2836031E-E2C3-4E28-BCD7-1646DB7E646FQ26853498-13108A0B-89E0-407F-B6B0-AADD93425F26Q28070036-FD20BEBB-6116-4B14-8634-29B3A3BDD3BDQ33433100-B0228244-008A-4771-AA9B-97DDDEE97DB8Q33648419-B987F0D4-CF1B-4515-987C-E1A1EAD326B1Q33688828-61675C09-717E-4219-9F4B-55930AC2CA0AQ33723716-28B7FD7C-C2D4-445B-9EC9-68DD49255C7AQ33799792-5A6ABB66-EA2F-4D40-927C-E7C873ADB6E1Q33869186-329D12A1-F499-4D69-993C-1A78C50B0BADQ34104106-FC752EB4-60B3-4871-B977-14BD753ABA88Q34202880-A38C70E7-96DC-41FA-8D4C-727C511EFAA1Q34284072-52B7A3CA-F755-43B4-88F1-9FE4AD718324Q34383454-01360A78-1B71-4C60-AE6B-F2A64B3D740BQ34551098-84552F6D-BC19-417F-AD50-AA530F00E261Q34561798-0F877ED4-16F4-4DD8-AA9C-DB15F83D3AEEQ34683833-58B14915-48F1-4539-AF39-11EFF0216348Q34745148-78EDF789-C6FC-4ECA-94CD-994A485DD513Q34798109-B1755E66-7460-4ADE-B4F9-67456BC11B5AQ34806765-D346C4DC-DCFC-4A33-B95B-6888D61ADD2FQ34969012-0B9D4C17-77A3-4A98-A2BA-D4367F5B5C2FQ35088734-18A6CC2A-F862-4BDE-A326-F7B730B2EA90Q35097709-D5786815-37A5-48AD-AF8C-EB7AA8A34F44Q35228976-A1CBF69E-43A1-4FA7-BABC-59EC2A536C9CQ35327231-A6E40253-4D78-43E9-B0D7-A1C9BF071479Q35344969-4F5D2A8C-090D-4649-ADDB-FDBE5A3625A0Q35681794-9A304E8E-E0D3-444F-82AF-A6A01478112DQ35850815-781CC932-CE22-414A-A510-E50741C4DCE2Q35863285-4D4A7E24-B5A7-4B86-BF25-5E9CE049D297Q36363277-BDFDF8D2-8465-4BC3-9B1C-D33A1D2BEEE6Q36543981-2CE9D382-1B0D-44D8-9F37-ACD5A6306AA8Q36561621-27619636-2E9B-4DC2-8A6F-7AC3DE434F15Q36725089-2B353BF7-D344-438A-87BA-FFEA67400F28Q36886772-256B8929-13B2-46D8-8489-06B7158A38A0Q36992184-4E65D453-051D-4239-A33C-7BB6FC20D299Q36999705-33FE16F8-71F9-47D3-B141-6CA23ACE8BC9Q37061991-B78DFEFA-0440-4B68-B293-CA67EEB709D8Q37071712-85ABB09B-03D4-4786-B385-85A32C83A104Q37275272-425D1360-8BE8-400F-B399-9C7CC0C7E473Q37302038-CF566D59-2FFE-40F5-B2DC-E3825BE0FB5DQ37327815-3425255C-F8F1-4075-896F-9E9C1C19D48A
P2860
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
@ast
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
@en
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
@nl
type
label
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
@ast
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
@en
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
@nl
prefLabel
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
@ast
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
@en
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
@nl
P2093
P1476
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
@en
P2093
Devalingam Mahalingam
Maccon Keane
Steven de Jong
P304
P356
10.1016/J.CTRV.2008.11.006
P577
2008-12-30T00:00:00Z